Clinical trials: MASH - Metabolic Dysfunction-Associated Steatohepatitis
Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors
The Development of MASLD Among Survivors of Breast or Colorectal Cancer
A metabolic issue is a condition where the body has problems with converting food into energy, using energy or storing energy properly.
- Conditions
- Breast Cancer Survivors, Colorectal (Colon or Rectal) Cancer Survivors, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- EVALUATE (NCT07280143)
- Where
- Switzerland
- Volunteers
- 200 people
- Sponsor
- University of Bern
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Betaine vs. Placebo for Serologically Diagnosed Metabolic Dysfunction-associated Steatohepatitis (MASH)
The study will evaluate whether betaine reduces liver injury in people with metabolic dysfunction-associated steatohepatitis (MASH). MASH is a type of liver disease that occurs in some people with fatty liver.
- Trial name
- NCT07276204
- Testing
- Betaine
- Volunteers
- 70 people
- Sponsor
- Southern California Institute for Research and Education
Metabolic Dysfunction-Associated Steatohepatitis(MASH)
Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults
This is a first-in-human, Phase I, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of QL2401 following single and multiple…
- Trial name
- NCT07331545
- Testing
- QL2401
- Where
- China
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD
This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis, Metabolic Dysfunction-associated Fatty Liver Disease
- Trial name
- NCT07632677
- Testing
- iLivTouch (Vibration-controlled transient elastography)
- Where
- 22 sites in China
- Volunteers
- 10,000 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Clinical Correlation Evaluation of the LIVERFASt Test for Diagnosing Important Liver Lesions of Fibrosis and Steatosis Against Magnetic Resonance Elastography (MRE) for Liver Fibrosis and MR-based Assessment of Steatosis, in Adult US Population.
This is a retrospective cross-sectional research intended to explore the utility of LIVERFASt in the clinical pathways for the detection of liver fibrosis and steatosis in comparison with the Magnetic Resonance Elastography (MRE)…
- Conditions
- Liver Fibrosis Due to NASH, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Alcohol Liver Disease
- Trial name
- LFMRECT (NCT06797596)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fibronostics USA, Inc
Acute Lung Injury(ALI), Liver Cirrhosis
Digital Early Warning System for Acute Lung Injury in Liver Surgery
This study aims to develop an explainable machine learning model that takes into account the characteristics of cardiopulmonary interactions.
- Conditions
- Acute Lung Injury(ALI), Liver Cirrhosis, ARDS, Human, MASLD
- Trial name
- NCT07070362
- Where
- 4 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated…
- Trial name
- NCT06920043
- Testing
- Efimosfermin
- Where
- 30 sites in United States
- Volunteers
- 42 people
- Sponsor
- GlaxoSmithKline
MASH - Metabolic Dysfunction-Associated Steatohepatitis
Resmiterom Efficacy & Safety in Patients With MASH
Phase 4 clinical trial study aims to further evaluate the safety and therapeutic efficacy of Resmetirom in Pakistani patients with fibroscan proven MASH.
- Trial name
- REZMASH (NCT07249788)
- Testing
- Resmetirom
- Where
- Pakistan
- Volunteers
- 165 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Non-alcoholic Fatty Liver Disease
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and…
- Trial name
- ZENITH-1 (NCT07221227)
- Testing
- Efimosfermin alfa
- Where
- 91 sites in United States, Australia and 7 more
- Volunteers
- 1,200 people
- Sponsor
- GlaxoSmithKline
Menopause, Metabolic Dysfunction Associated Steatotic Liver Disease
COmmencing Menopausal HOrmone Replacement Therapy and the Effect on Metabolic-dysfunction Associated Steatotic Liver Disease: a Pilot Mechanistic Study
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide, currently affecting approximately 1-in-4 people globally.
- Trial name
- NCT06704516
- Testing
- Menopausal hormone therapy
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)
Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity.
- Trial name
- AdipoDROMExpo (NCT07330830)
- Where
- 3 sites in French Guiana, Guadeloupe and 1 more
- Volunteers
- 600 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).
- Trial name
- NASHGEN-2 (NCT05519475)
- Testing
- ALN-HSD
- Where
- 71 sites in United States, Japan and 2 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with metabolic dysfunction-associated steatotic liver disease (MASLD) who have the patatin-like phospholipase…
- Trial name
- NCT05395481
- Testing
- LY3849891
- Where
- 16 sites in United States, Japan and 1 more
- Volunteers
- 115 people
- Sponsor
- Eli Lilly and Company
Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity
Efficacy and Safety of CS0159 Combined With Semaglutide in MASH Patients With Obesity and T2DM
This is an exploratory study evaluating CS0159 in combination with Semaglutide in MASH patients with obesity and T2DM.
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH), Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT06492330
- Testing
- CS0159
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Metabolic Dysfunction-associated Steatohepatitis (MASH)
A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating the efficacy and safety of UBT251 in MASH subjects.
- Trial name
- MASH (NCT07145151)
- Testing
- UBT251
- Where
- China
- Volunteers
- 156 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
MASH - Metabolic Dysfunction-Associated Steatohepatitis
High-Risk Transcriptome Molecular Prediction Study of MASH-Associated Colorectal Polyps
The goal of this observational study is to learn about the molecular characteristics of colorectal polyps in patients with metabolic dysfunction-associated steatohepatitis (MASH) compared to individuals without fatty liver, and…
- Trial name
- NCT07463287
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai East Hospital
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Assessment of Non-Invasive Testing in Major Liver-Related Outcomes
This is a general clinical research protocol to study the clinical evaluation, investigation and long-term follow up of patients who have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and MetALD (MASLD and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD, MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
- Trial name
- MAIL-NIT (NCT06986447)
- Where
- 8 sites in United States
- Volunteers
- 1,689 people
- Sponsor
- HRI-MAIL-NIT
Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is researching an experimental drug called ALN-PNP (called "study drug"). This is a first in human study. The study drug is not approved by any public health agency such as the United States Food and Drug…
- Trial name
- NCT05648214
- Testing
- ALN-PNP
- Where
- 6 sites in United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Obesity, Liver Diseases
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting…
- Conditions
- Obesity, Liver Diseases, Liver Fibrosis, Liver Fat
- Trial name
- NCT06138821
- Testing
- ESG + lifestyle modification, Lifestyle modification
- Where
- 2 sites in United States
- Volunteers
- 132 people
- Sponsor
- Pichamol Jirapinyo, MD, MPH
MASH-related HCC
Long Term Prediction of MASH-related HCC Risk by Proteomics
MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), affects over 25% of the global population and is increasingly associated with obesity and type 2 diabetes.
- Trial name
- PROTEOMASH (NCT07332611)
- Testing
- Proteomics
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Bordeaux